OCS Earnings Date: Nov 3, 2026 — Oculis Holding AG
NASDAQ · Healthcare · Biotechnology
Updated
When is OCS's next earnings date?
Oculis Holding AG (OCS) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:05 PM ET (after market close). The consensus estimate is EPS of -$0.49 on revenue of $247,230.
How did OCS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Oculis Holding AG posted EPS of -$0.20 versus the -$0.48 estimate, a beat of 58.3%. Revenue was $392,150 against a $216,839 estimate. The stock's 1-day post-earnings move was +2.4%.
How much does OCS stock move after earnings?
OCS beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 1.7% (up or down) in the day after earnings.
About Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.48 | -0.20 | +58.33% | $392,150 | ✅ Beat | +2.42% | +3.55% | -1.70% |
| 2026-05-11 | Q1 2026 | -0.49 | -0.63 | -27.55% | $266,845 | ❌ Miss | -6.86% | -14.03% | -66.40% |
| 2026-03-03 | Q4 2025 | -0.43 | -0.53 | -23.26% | $514,161 | ❌ Miss | +0.54% | +3.92% | -1.96% |
| 2025-11-10 | Q3 2025 | -0.50 | -0.40 | +20.00% | $303,761 | ✅ Beat | -0.10% | -1.39% | +6.23% |
| 2025-08-21 | Q2 2025 | -0.53 | -0.57 | -7.55% | $307,416.8 | ❌ Miss | +0.28% | -8.15% | -0.39% |
| 2025-03-11 | Q4 2024 | -0.38 | -0.76 | -100.00% | $3,419 | ❌ Miss | +2.39% | +3.10% | -11.74% |
| 2024-11-07 | Q3 2024 | -0.57 | -0.55 | +3.51% | $249,538 | ✅ Beat | -0.53% | -12.85% | -2.72% |
| 2024-08-27 | Q2 2024 | -0.47 | -0.56 | -19.15% | $270,887 | ❌ Miss | +0.51% | +1.27% | +1.90% |
Showing last 8 quarters.